Evidence map›Paper›PMID 39507617›Full record

ArticleOpen journal of immunology2024

The First Pilot Epigenetic Type Improvement of Neuropsychiatric Symptoms in a Polymorphic Dopamine D2 (-DRD2/ANKK (Taq1A)), OPRM1 (A/G), DRD3 (C/T), and MAOA (4R) Compromised Preadolescence Male with Putative PANDAS/CANS: Positive Clinical Outcome with Precision-Guided DNA Testing and Pro-Dopamine Regulation (KB220) and Antibacterial Therapies.

Kenneth Blum, Igor Elman, David Han, Colin Hanna, David Baron, Ashim Gupta, Shan Kazmi, Jag Khalsa, Debasis Bagchi, Thomas McLaughlin and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open journal of immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Kenneth BlumDivision of Addiction Research & Education, Center for Sports and Mental Health, Western University of Health Sciences, Pomona, CA, USA.
Igor ElmanDepartment of Psychiatry, Harvard School of Medicine, Cambridge, MA, USA.
David HanDepartment of Management Science and Statistics, University of Texas, San Antonio, TX, USA.
Colin HannaBehavioral Neuropharmacology and Neuroimaging Laboratory, Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.
David BaronDivision of Addiction Research & Education, Center for Sports and Mental Health, Western University of Health Sciences, Pomona, CA, USA.
Ashim GuptaFuture Biologics, Lawrenceville, GA, USA.
Shan KazmiDivision of Addiction Research & Education, Center for Sports and Mental Health, Western University of Health Sciences, Pomona, CA, USA.
Jag KhalsaDepartment of Microbiology, Immunology, & Tropic Diseases, School of Medicine, Georgetown University, Washington DC, USA.
Debasis BagchiDepartment of Pharmaceutical Sciences, College of Pharmacy, Texas Southern University, Houston, TX, USA.
Thomas McLaughlinThe Kenneth Blum Behavioral & Neurogenetic Institute, LLC., Austin, TX, USA.
Rajendra D BadgaiyanDepartment of Psychiatry, School of Medicine, Case Western University, Cleveland, OH, USA.
Edward J ModestinoBrain and Behavior Laboratory, Curry College, Milton, MA, USA.
Drew EdwardsThe Neurogenesis Project, Jacksonville, FL, USA.
Catherine A DennenDepartment of Family Medicine, Jefferson Health Northeast, Philadelphia, PA, USA.
Eric R BravermanThe Kenneth Blum Behavioral & Neurogenetic Institute, LLC., Austin, TX, USA.
Abdalla BowirratDepartment of Molecular Biology, Adelson School of Medicine, Ariel University, Ariel, Israel.
Keerthy SunderDivision of Neuromodulation Research, Karma Doctors & Karma TMS, Palm Springs, CA, USA.
Kevin MurphyDivision of Personalized Interventions, Peak Logic, Del Mar, CA, USA.
Nicole JafariDivision of Personalized Medicine, Cross-Cultural Research & Educational Institute, San Clemente, CA, USA.
Foojan ZeineAwareness Integration Institute, San Clemente, CA, USA.
Paul R CarneyDivision Pediatric Neurology, School of Medicine, University of Missouri, Columbia, MO, USA.
Mark S GoldDepartment of Psychiatry, School of Medicine, Washington University, St. Louis, MO, USA.
Kai-Uwe LewandowskiDivision of Personalized Pain Therapy, Center for Advanced Spine Care of Southern Arizona, Tucson, AZ, USA.
Alireza SharafshahCellular and Molecular Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
Aryeh R PollackThe Kenneth Blum Behavioral & Neurogenetic Institute, LLC., Austin, TX, USA.
Panayotis K ThanosBehavioral Neuropharmacology and Neuroimaging Laboratory, Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.

Funding

A Systematic Medical Approach to Reward Transformation (SMART) for Brain Health in Opioid Use DisorderR41MD012318 · NIMHD · VERSA INTEGRATED SOLUTIONS, INC. · PI BLUM, KENNETH, GONDRE-LEWIS, MARJORIE C · 2017 to 2017
$221k
Dopamine Neurotransmission in AddictionI01CX000479 · VA · VA WESTERN NEW YORK HEALTHCARE SYSTEM · PI BADGAIYAN, RAJENDRA D · 2013 to 2014
–
CSRD VA I01 CX000479NIMHD NIH HHS R41 MD012318
6 · The paper itself

Abstract

Pediatric autoimmune neuropsychiatric disorders associated with or without streptococcal and other bacterial infections (PANDAS/CANS) are emerging as a featured pediatric disorder. Although there is some controversy regarding treatment approaches, especially related to the behavioral sequelae, we have hypothesized in other published work that it is characterized by the rapid onset of Reward Deficiency Syndrome (RDS) in children. We propose utilizing a multi-systems biological approach involving the coupling of genetic addiction risk testing and pro-dopamine regulation (KB220/POLYGEN

Indexed as

Antibacterial TherapyCANSGenetic Addiction Risk Testing (GARS)HypodopaminergiaInfectionsPANDASPolymorphismsPro-Dopamine Regulation

Identifiers

PMID39507617
PMCPMC11539193

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.